NF2 status of meningiomas is associated with tumour localization and histology
- PMID: 11439370
- DOI: 10.1002/path.909
NF2 status of meningiomas is associated with tumour localization and histology
Abstract
In approximately 60% of sporadic meningiomas, the tumour suppressor gene NF2, located on chromosome 22q, is inactivated. Mutations in the NF2 gene have been specifically reported in transitional and fibrous, but not meningothelial, meningiomas. Since meningothelial meningiomas frequently occur in anterior parts of the skull base, the association between tumour localization, size, histological subtype and NF2 status was investigated in a group of 42 sporadic meningiomas. NF2 status was determined by LOH analysis, karyotyping and FISH. Tumour size and site were evaluated by CT scans and MRIs. A strong correlation between tumour localization in the anterior skull base and intact 22q was revealed (p=0.003). On the other hand, tumour localization at the convexity was associated with disruption of NF2 (p=0.023). Furthermore, an association between chromosome 22 status and histological subtype was observed: abnormalities of chromosome 22q were more frequent in transitional and fibrous meningiomas than in the meningothelial variant (p<0.001). Also, the meningothelial meningiomas were more often located in the anterior skull base (p<0.006). Based on these findings, it is concluded that an alternative histogenesis and genetic pathway is likely to exist for meningiomas arising in the anterior skull base.
Copyright 2001 John Wiley & Sons, Ltd.
Similar articles
-
Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas.Cancer Res. 1999 Dec 1;59(23):5995-8. Cancer Res. 1999. PMID: 10606247
-
Lack of genetic and epigenetic changes in meningiomas without NF2 loss.J Pathol. 2006 Mar;208(4):564-73. doi: 10.1002/path.1909. J Pathol. 2006. PMID: 16353169
-
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.Nat Genet. 1994 Feb;6(2):180-4. doi: 10.1038/ng0294-180. Nat Genet. 1994. PMID: 8162072
-
[The molecular genetics of meningiomas and genotypic/phenotypic correlations].Rev Neurol (Paris). 2003 Sep;159(8-9):727-38. Rev Neurol (Paris). 2003. PMID: 13679715 Review. French.
-
Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):353-7. doi: 10.1097/01.pai.0000213114.27978.3a. Appl Immunohistochem Mol Morphol. 2007. PMID: 17721284 Review.
Cited by
-
Genetic/molecular alterations of meningiomas and the signaling pathways targeted.Oncotarget. 2015 May 10;6(13):10671-88. doi: 10.18632/oncotarget.3870. Oncotarget. 2015. PMID: 25965831 Free PMC article. Review.
-
Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.BMC Genomics. 2007 Jan 12;8:16. doi: 10.1186/1471-2164-8-16. BMC Genomics. 2007. PMID: 17222329 Free PMC article.
-
Novel Medical Therapies in Meningiomas.Adv Exp Med Biol. 2023;1416:213-223. doi: 10.1007/978-3-031-29750-2_16. Adv Exp Med Biol. 2023. PMID: 37432630
-
Merlin, the NF2 gene product.Pathol Oncol Res. 2013 Jul;19(3):365-73. doi: 10.1007/s12253-013-9644-y. Epub 2013 May 12. Pathol Oncol Res. 2013. PMID: 23666797 Review.
-
Advances in meningioma genetics: novel therapeutic opportunities.Nat Rev Neurol. 2018 Feb;14(2):106-115. doi: 10.1038/nrneurol.2017.168. Epub 2018 Jan 5. Nat Rev Neurol. 2018. PMID: 29302064 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
